Zmiany aktywnosci wybranych enzymow z rodziny cytochromu P-450 w interakcji leku roslinnego z lekiem syntetycznym

• Autorzy: Maciejewska M , Bogacz A. , Mrozikiewicz P.M.

Warianty tytułu

EN

Changes of cytochrome P450 enzymes activity in herb-drug interaction

• Języki publikacji: PL

Abstrakty

PL

W metabolizm ksenobiotyków zaangażowane są enzymy z rodziny cytochromu P450 – transbłonowe białka zlokalizowane w retikulum endoplazmatycznym i mitochondriach wielu tkanek organizmu. Wykazują one zmienność międzygatunkową polegającą na różnym poziomie ich aktywności i regulacji u poszczególnych gatunków. Konserwatywność i podobieństwo sekwencyjne niektórych z nich pozwala na ustalenie u zwierząt sekwencji analogicznych do ludzkich i prowadzenie badań z udziałem organizmów modelowych. Aktywność enzymów CY P modulowana jest przez zróżnicowane substancje egzogenne i endogenne poprzez indukcję bądź inhibicję. Wzajemne oddziaływania przyjmowanych przez pacjenta leków syntetycznych i preparatów roślinnych, wielokrotnie niekorzystnie wpływające na końcowy efekt ich stosowania, stanowią jeden z ważnych problemów współczesnej farmakoterapii. W sytuacji braku dostatecznej wiedzy na temat zagrożeń wynikających z ich wzajemnej relacji oraz bezpiecznego stosowania, konieczne jest podjęcie badań w kierunku zdefiniowania potencjalnych następstw tego typu interakcji. W tym celu niezbędne jest podjęcie analizy oddziaływania preparatów roślinnych na poziom ekspresji enzymów CY P o niezwykle ważnych implikacjach klinicznych i toksykologicznych. Poznanie właściwości farmakokinetycznych farmaceutyków, a także preparatów roślinnych stosowanych w leczeniu wielu schorzeń, stwarza realną szansę na eliminację lub zminimalizowanie interakcji pomiędzy substancjami aktywnymi.

EN

Cytochrome P450 enzymes belongs to a large family of hemoproteins and are mainly involved in the biotransformation of xenobiotics. Transmembrane protein are localized in the endoplasmic reticulum and mitochondria of many tissues. They indicate a variety of interspecies that depend on differences exist in the expression and catalytic activities. Conservatism and similarity of sequence allow to establish the analogical human sequences in animals and, in consequence, to carry out the studies on animal models. Many drugs may cause an increase or decrease the activity of various CY P isozymes. This is a major source of adverse drug interactions that are a result of inhibition or induction of cytochrome P450 enzymes. The investigatin of the ability to induce the interactions with synthetic drugs is very important for the safe evaluation of herbal pharmacotherapy. There is a need to perform preclinical and clinical research in order to explain mechanisms and basis for interactions between herbal and synthetic drugs. In this aim, it is necessary to investigate effect of medicinal plants on expression level of genes involved in xenobiotics biotransformation.

Słowa kluczowe

PL

ksenobiotyki; leki roslinne; cytochrom P-450; aktywnosc enzymatyczna; interakcje lekowe; leki syntetyczne; biotransformacja

• Wydawca: -
• Czasopismo: Herba Polonica
• Rocznik: 2008
• Tom: 54
• Numer: 1
• Opis fizyczny: s.57-67,rys.,tab.,bibliogr.

Twórcy

autor

Maciejewska M

• Instytut Roslin i Przetworow Zielarskich, ul.Libelta 27, 61-707 Poznan

autor

Bogacz A.

autor

Mrozikiewicz P.M.

Bibliografia

• 1. Venkataramanan R, Komoroski B, Strom S. In vitro and in vivo assessment of herb drug interactions. Life Sci 2006; 78:2105-15.
• 2. Beirle I, Meibohm B, Derendorf H. Gender differences in pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Therap 1999; 37:529-47.
• 3. Riddick DS, Lee C, Bhathena A, Timsit YE , Cheng PY, Morgan ET , Prough RA, Ripp SL , Miller KK , Jahan A, Chiang JY . Transcriptional suppression of cytochrome P450 genes by endogenous and exogenous chemicals. Drug Metab Dispos 2004; 32:367-75.
• 4. Mrozikiewicz PM, Klusek T. Farmakogenetyka i nutragenomika – nowe narzędzia w profilaktyce i leczeniu chorób. Panacea 2005; 1(10).
• 5. T redger M, Path M, Stoll S. Cytochromes P450 – their impact on drug treatment. Hospital Pharmacist 2002; 9:167-73.
• 6. Y asui H, Hayashi S, Sakurai H. Possible involvement of singlet oxygen species as multiple oxidants in p450 catalytic reactions. Drug Metab Pharmacokinet 2005; 20:1-13.
• 7. Zuber R, Anzenbacherova E, Anzenbacher P. Cytochromes P450 and experimental models of drug metabolism. J Cell Mol Med 2002; 6:189-98.
• 8. E agling V, Tija J, Back D. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol 1998;45:107-14.
• 9. T akada T, Ogino M, Miyata M, Shimada M, Nagata K, Yamazoe Y. Differences in transactivation between rat CY P3A1 and human CY P3A4 genes by human pregnane X receptor. Drug Metab Pharmacokinet 2004; 19:103-13.
• 10. E liasson E, Mkrtchian S, Halpert J, Ingelman-Sundberg M. Substrate-regulated, cAMP-dependent phosphorylation, denaturation, and degradation of glucocorticoid-inducible rat liver cytochrome P450 3A1. J Biol Chem 1994; 269:18378-83.
• 11. G uengerich FP. Comparisons on catalytic selectivity of cytochrome P450 subfamily enzymes from different species. Chem Biol Interact 1997; 106:161.
• 12. A iba T, Yoshinaga M, Ishida K, Takehara Y, Hashimoto Y. Intestinal expression and metabolic activity of the CY P3A subfamily in female rats. Biol Pharm Bull 2005; 28:311-5.
• 13. Ma MK, Woo MH, Mcleod HL. Genetic basis of drug metabolism. Am J Health Syst Pharm 2002; 59:2061-9.
• 14. K alow W. Pharmacogenetics, pharmacogenomics, and pharmacobiology. Clin Pharmacol Ther 2001; 70:1-4.
• 15. Venhorst J, ter Laak AM, Commandeur JN, Funae Y, Hiroi T, Vermeulen NP. Homology modeling of rat and human cytochrome P450 2D (CY P2D) isoforms and computational rationalization of experimental ligand-binding specificities. J Med Chem 2003; 46:74-86.
• 16. G awrońska-Szklarz B. Influence of genetic factors on drug treatment efficacy and safety in cardiovascular diseases. Acta Angiol 2003; 9:1-15.
• 17. K obayashi K, Urashima K, Shimada N, Chiba K. Selectivities of human cytochrome P450 inhibitors toward rat P450 isoforms: study with cDNA-expressed systems of the rat. Drug Metab Dispos 2003; 3:833-6.
• 18. Moore LB, Goodwin B, Jones SA , Wisely GB, Serabjit-Singh CJ , Willson TM, Collins JL , Kliewer SA . St. John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 2000; 97:7500-2.
• 19. O bach R. Inhibition of human cytochrome P450 enzymes by constituents of St. John’s wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 2000; 294:88-95.
• 20. W entworth JM, Agostini M, Love J, Schwabe JW , Chatterjee VK. St John’s wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol 2000; 166:R11-6.
• 21. Durr D, Stieger B, Kullak-Ublick GA , Rentsch KM, Steinert HC, Meier PJ, Fattinger K. St John’s wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CY P3A4. Clin Pharmacol Ther 2000; 68:598-604.
• 22. C ui Y, Ang C, Beger R, Heinze T. In vitro metabolism of hyperforin in rat liver microsomal systems. Drug Metab Dispo 2004; 32:28-34.
• 23. W ang EJ , Li Y, Lin M, Chen L, Stein AP, Reuhl KR, Yang CS . Protective effects of garlic and related organosulfur compounds on acetaminophen-induced hepatotoxicity in mice. Toxicol Appl Pharmacol1996; 136:146-54.
• 24. Markowitz JS , Devane CL , Chavin KD, Taylor RM, Ruan Y, Donovan JL . Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Clin Pharmacol Ther 2003; 74:170-7.
• 25. G orski JC , Huang SM, Pinto A, Hamman MA, Hilligoss JK , Zaheer NA, Desai M, Miller M, Hall SD. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther 2004; 75:89-100.
• 26. T ada Y, Kagota S, Kubota Y, Nejime N, Nakamura K, Kunitamo M, Shinozuka K. Long-term feeding f Ginkgo biloba extract impairs peripheral circulation and hepatic function in aged spontaneouslyhypertensive rats Biol Pharm Bull 2008; 31:68-72.
• 27. C hang TH, Chen J, Teng XW. Distinct role of bilobalide and ginkolide A in the modulation of rat CY P2B1 and CY P3A23 gene expression by Ginkgo biloba extract in cultured hepatocytes. Drug Metab Dispos 2006; 34:234-42.
• 28. Hellum BH, Nilsen OG . The in vitro inhibitory potential of trade herbal products on human CY P2D6- mediated metabolism and the influence of ethanol. Basic Clin Pharmacol Toxicol 2007; 101:350-8.
• 29. Donovan JL , DeVane CL , Chavin KD, Wang JS , Gibson BB, Gefroh HA, Markowitz JS . Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CY P3A4 activity and no effect on CY P2D6activity in healthy volunteers. Drug Metab Dispos 2004; 32:1333-6.
• 30. A nderson GD, Rosito G, Mohustsy MA, Elmer GW . Drug interaction potential of soy extract and Pana ginseng. J Clin Pharmacol 2003; 43:643-8.
• 31. L ee HC, Hwang SG , Lee YG , Sohn HO, Lee DW, Hwang SY , Kwak YS , Wee JJ , Joo WH, Cho YK , Moon JY . In vivo effects of Panax ginseng extracts on the cytochrome P450-dependent monooxygenase system in the liver of 2,3,7,8-tetrachlorodibenzo-p-dioxin-exposed guinea pig. Life Sci 2002; 71:759-69.
• 32. Hang TK , Chen J, Benetton SA . In vitro effect of standardized ginseng extracts and individual ginsenoside on the catalytic activity of human CY P1A1, CY P1A2, and CY P1B1. Drug Metab Dispos 2002; 30:378-84.
• 33. Foster BC, Vandenhoek S, Hana J, Krantis A, Akhtar MH, Bryan M, Budzinski JW , Ramputh A, Arnason JT . In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. Phytomedicine 2003; 10:334-42.
• 34. Y oshinari K, Sato T, Okino N, Sugatani J, Miwa M. Expression and induction of cytochromes p450 in rat white adipose tissue. J Pharmacol Exp Ther 2004; 311:147-54.
• 35. C orreia MA. Rat and human liver cytochromes P450. Substrate and inhibitor specificities and functionalmarkers. In: Oritz the Montellano, PR.(eds.) Cytochrome P450. Structure, mechanism, and biochemistry 2nd ed. New York–London 1995; Appendix B:607-30.
• 36. Halpert JR. Multiplicity of steroid-inducible cytochromes P-450 in rat liver microsomes. Arch Biochem Biophys 1988; 263:59-68.
• 37. T yndale RF, Li Y, Li NY, Messina E, Miksys S, Sellers EM. Characterization of cytochrome P-450 2D1 activity in rat brain: Hihg-affinity kinetics for dextromrthorphan. Drug Metab Dispos 1999; 27:924-30.
• 38. K ageyama M, Namiki H, Fukushima H, Ito Y, Shibata N, Takada K. In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CY P) 3A in rats. Biol Pharm Bull 2005; 28:316-22.
• 39. E agling VA, Tjia JF, Back DJ. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol 1998; 45:107-14.
• 40. Hoen PA, Bijsterbosch MK, van Berkel TJ , Vermeulen NP, Commandeur JN. Midazolam is a phenobarbitallikecytochrome p450 inducer in rats. J Pharmacol Exp Ther 2001; 299:921-7.
• 41. C hang T, Levine M, Bellward GD. Selective inhibition of rat hepatic microsomal cytochrome P-450. II .Effect of the in vitro administration of cimetidine. J Pharmacol Exp Ther 1992; 260:1450-5.
• 42. W ang JF, Yang Y, Sullivan MF, Min J, Cai J, Zeldin DC, Xiao YF, Morgan JP. Induction of cardiac cytochromep450 in cocaine-treated mice. Exp Biol Med (Maywood) 2002; 227:182-8.\